Research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a report issued on Friday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Wednesday, February 21st.
Check Out Our Latest Stock Analysis on DBVT
DBV Technologies Trading Down 2.7 %
DBV Technologies (NASDAQ:DBVT – Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. The business had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the prior year, the firm posted ($0.23) earnings per share. On average, equities analysts forecast that DBV Technologies will post -0.88 earnings per share for the current year.
Hedge Funds Weigh In On DBV Technologies
Several hedge funds have recently made changes to their positions in DBVT. Point72 Asset Management L.P. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at $5,914,000. Millennium Management LLC increased its position in shares of DBV Technologies by 53.9% in the 4th quarter. Millennium Management LLC now owns 871,996 shares of the company’s stock valued at $1,334,000 after acquiring an additional 305,562 shares during the period. Optiver Holding B.V. increased its position in shares of DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after acquiring an additional 235,337 shares during the period. ExodusPoint Capital Management LP acquired a new position in shares of DBV Technologies in the 2nd quarter valued at $352,000. Finally, BlackRock Inc. increased its position in shares of DBV Technologies by 16.5% in the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock valued at $1,093,000 after acquiring an additional 97,412 shares during the period. 71.74% of the stock is owned by institutional investors and hedge funds.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
See Also
- Five stocks we like better than DBV Technologies
- Election Stocks: How Elections Affect the Stock Market
- Here are the Pros and Cons of Using Options Call Debit Spreads
- How to buy stock: A step-by-step guide for beginners
- Carmax Returns to the Bargain Basement: Buy the Dip?
- ESG Stocks, What Investors Should Know
- Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.